Rockwell Medical, Inc. — FY2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021; this is an annual report, not a standalone fourth-quarter report. Rockwell Medical is a commercial-stage biopharmaceutical company and a major U.S. supplier of hemodialysis concentrates. Its business combines concentrate manufacturing with FDA-approved iron therapies Triferic and Triferic AVNU, and development of its ferric pyrophosphate citrate (FPC) platform.
Financial results and liquidity
| Metric | 2021 | 2020 |
|---|---|---|
| Net sales | $61.9 million | $62.2 million |
| Cost of sales | $64.4 million | $59.5 million |
| Gross profit (loss) | $(2.4) million; (3.9)% margin | $2.7 million; 4.4% margin |
| Operating loss | $(30.3) million | $(28.4) million |
| Net loss | $(32.7) million; $(0.35) per share | $(30.9) million; $(0.41) per share |
| Cash used in operating activities | $(33.5) million | $(29.6) million |
- At December 31, 2021, cash and cash equivalents were $13.3 million, available-for-sale investments were $9.2 million, working capital was $14.3 million, and stockholders’ equity was $2.5 million. Accumulated deficit was $370.1 million.
- Term-loan principal outstanding was approximately $21.8 million ($20.6 million net of unamortized costs and discount), due March 2025. Scheduled principal payments include $7.75 million in 2022. The loan is secured by substantially all company assets and includes financial covenants.
- Dialysis concentrates generated $60.9 million, or approximately 98% of 2021 revenue. Triferic sales remained about $1.1 million. The filing reports no operating profitability.
Changes versus 2020
- Revenue declined 0.4%, while cost of sales rose 8.2%; the company moved from gross profit to gross loss. Management attributed the deterioration mainly to inflation in concentrate manufacturing and operating costs, including transportation and labor.
- Operating loss widened 6.7%. Selling and marketing expense fell 27.2% after reduced Triferic marketing and headcount; research and product development expense fell 3.6%, and general and administrative expense fell 5.2%.
- Operating cash use increased by $3.9 million. Cash and investments totaled $22.4 million at year-end, versus $58.7 million at the end of 2020.
Outlook, risks and unusual items
- Going concern and financing: The auditor identified going concern as a critical audit matter. The filing describes substantial doubt arising from recurring losses, cash burn and the concentrates business operating at a loss. Subsequent to year-end, DaVita amended its supply agreement and invested $7.5 million in preferred stock on April 7, 2022. A second $7.5 million tranche is conditional on Rockwell raising an additional $15 million by June 30, 2022. The amended supply agreement also requires at least $10 million in cash and specified cost actions. Management said these measures, pricing changes and cost controls were expected to fund operations and anticipated capital expenditures for 12 months; additional capital would still be needed for its strategic plans. These conditions are not assurances of future funding or profitability.
- Concentrates outlook: The April 2022 DaVita amendment provides for higher pricing effective May 1 and pass-through of certain inflationary costs, subject to caps. Management expects a double-digit year-over-year increase in concentrates revenue assuming steady sales volumes and expects improved margins, but profitability depends on cost containment. DaVita accounted for 47% of 2021 sales; Baxter direct sales were approximately 26%. Loss of a major customer or failure to renegotiate other contracts could materially affect results.
- Debt and contract risks: The Innovatus loan has liquidity and sales covenants; Rockwell reported compliance with financial covenants at year-end but disclosed a waived reporting-covenant issue. Default could accelerate repayment and expose pledged assets. The DaVita financing restricts additional debt without consent, subject to stated exceptions. Baxter had reserved its right to seek a refund of part of its upfront payment in certain termination circumstances; Rockwell disputes the claim.
- Development and commercialization: Rockwell planned a Phase II home-infusion study for iron-deficiency anemia in 2022, subject to adequate capital. The filing also says the home-infusion IND was on clinical hold while required studies were performed. For acute heart failure, the company expected to seek FDA feedback on a proposed development program in the second half of 2022. Triferic adoption remains limited; both approved products are reimbursed within the dialysis bundle, and a U.S. commercialization partner is being sought. The company significantly scaled back its Triferic sales organization in 2021.
- Other risks and events: COVID-19, supply-chain and inflation pressures, customer concentration, product inventory expiration, regulatory and clinical uncertainty, and competition could affect operations. Rockwell had $32.6 million of anticipated purchase obligations through 2022. Nasdaq had granted an extension to June 6, 2022 to regain the minimum bid-price requirement. The SEC concluded its investigation in January 2022 and said it did not intend to recommend enforcement action against the company.
Most important facts for investors to verify
- Whether Rockwell raised the required additional $15 million by June 30, 2022, received DaVita’s conditional second tranche, and maintained the required cash minimum.
- Whether the amended DaVita pricing and cost-sharing terms improved concentrate gross margins, and whether cost savings and pricing changes were achieved without triggering contract caps or termination rights.
- Actual operating cash burn, available liquidity, debt payments and covenant compliance compared with management’s 12-month funding assessment.
- The status of the home-infusion IND hold, Phase II trial timing and funding, and progress in the acute-heart-failure program.
- Triferic adoption, partner prospects, inventory shelf life and customer concentration; also verify the outcome of the Baxter upfront-payment dispute and Nasdaq listing compliance.